IL145764A0 - Pyrazolobenzodiazepines as cdk2 inhibitors - Google Patents

Pyrazolobenzodiazepines as cdk2 inhibitors

Info

Publication number
IL145764A0
IL145764A0 IL14576400A IL14576400A IL145764A0 IL 145764 A0 IL145764 A0 IL 145764A0 IL 14576400 A IL14576400 A IL 14576400A IL 14576400 A IL14576400 A IL 14576400A IL 145764 A0 IL145764 A0 IL 145764A0
Authority
IL
Israel
Prior art keywords
pyrazolobenzodiazepines
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
IL14576400A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL145764A0 publication Critical patent/IL145764A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14576400A 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors IL145764A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21
PCT/EP2000/003394 WO2000064900A1 (en) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors

Publications (1)

Publication Number Publication Date
IL145764A0 true IL145764A0 (en) 2002-07-25

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14576400A IL145764A0 (en) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors

Country Status (33)

Country Link
US (3) US6440959B1 (ar)
EP (1) EP1185529B1 (ar)
JP (1) JP3746680B2 (ar)
KR (1) KR100481757B1 (ar)
CN (2) CN1279029C (ar)
AR (1) AR023542A1 (ar)
AT (1) ATE279413T1 (ar)
AU (1) AU768667B2 (ar)
BR (1) BR0009887A (ar)
CA (1) CA2367704C (ar)
CO (1) CO5170444A1 (ar)
CZ (1) CZ20013738A3 (ar)
DE (1) DE60014893T2 (ar)
DK (1) DK1185529T3 (ar)
ES (1) ES2228522T3 (ar)
HK (1) HK1046278B (ar)
HR (1) HRP20010742A2 (ar)
HU (1) HUP0300318A3 (ar)
IL (1) IL145764A0 (ar)
JO (1) JO2248B1 (ar)
MA (1) MA26782A1 (ar)
NO (1) NO20015065L (ar)
NZ (1) NZ514523A (ar)
PE (1) PE20010054A1 (ar)
PL (1) PL200933B1 (ar)
PT (1) PT1185529E (ar)
RU (1) RU2249593C2 (ar)
SI (1) SI1185529T1 (ar)
TR (1) TR200103016T2 (ar)
TW (1) TW585866B (ar)
WO (1) WO2000064900A1 (ar)
YU (1) YU73101A (ar)
ZA (1) ZA200108016B (ar)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6520951B1 (en) 1996-09-13 2003-02-18 Scimed Life Systems, Inc. Rapid exchange catheter with detachable hood
ES2309209T3 (es) * 2001-11-13 2008-12-16 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,4-benzodiazepinas sustituidas y uso de las mismas para el tratamiento del cancer.
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
JP2006519236A (ja) * 2003-02-27 2006-08-24 アボット・ラボラトリーズ 複素環式キナーゼ阻害剤
DK1802625T3 (da) * 2004-10-13 2008-09-01 Hoffmann La Roche Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer
CA2624025A1 (en) * 2005-10-14 2007-04-19 F. Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
KR20150081370A (ko) 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SG11201404596UA (en) * 2012-02-02 2014-10-30 Senex Biotechnology Inc Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JP7139323B2 (ja) * 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
AU2017376353B2 (en) 2016-12-13 2020-02-06 Transthera Sciences (Nanjing), Inc. Multi-kinase inhibitor compound, and crystal form and use thereof
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US20230212167A1 (en) * 2020-05-08 2023-07-06 Transthera Sciences (Nanjing), Inc. Method for synthesizing anti-tumor compound and intermediates thereof
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
US20240245704A1 (en) * 2021-05-10 2024-07-25 Transthera Sciences (Nanjing), Inc. Pharmaceutical composition and use of multi-kinase inhibitor
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (en) * 2022-08-02 2024-02-08 Lab1636, Llc Use of a gaba-a pam for reduction of tactile hypersensitivity
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071092A1 (en) * 1991-06-14 1992-12-15 Roger M. Freidinger 1,4-benzodiazepines with 5-membered heterocyclic rings
ES2239779T3 (es) 1996-10-02 2005-10-01 Novartis Ag Derivados de pirimidina y procedimientos para la preparacion de los mismos.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
BR0009887A (pt) 2002-01-22
CA2367704A1 (en) 2000-11-02
CN1348455A (zh) 2002-05-08
HRP20010742A2 (en) 2002-12-31
JO2248B1 (ar) 2004-10-07
CA2367704C (en) 2008-06-17
JP3746680B2 (ja) 2006-02-15
AU768667B2 (en) 2003-12-18
SI1185529T1 (en) 2005-02-28
CN1196703C (zh) 2005-04-13
YU73101A (sh) 2004-05-12
HK1046278A1 (en) 2003-01-03
CZ20013738A3 (cs) 2002-08-14
HUP0300318A3 (en) 2004-11-29
DE60014893T2 (de) 2005-10-13
TR200103016T2 (tr) 2002-04-22
HUP0300318A2 (hu) 2003-06-28
JP2002543081A (ja) 2002-12-17
ATE279413T1 (de) 2004-10-15
NO20015065D0 (no) 2001-10-18
HK1046278B (zh) 2005-08-12
TW585866B (en) 2004-05-01
US6916923B2 (en) 2005-07-12
KR20010112435A (ko) 2001-12-20
AU4748000A (en) 2000-11-10
US6838558B2 (en) 2005-01-04
NZ514523A (en) 2003-11-28
ZA200108016B (en) 2003-03-26
RU2249593C2 (ru) 2005-04-10
US6440959B1 (en) 2002-08-27
CN1603314A (zh) 2005-04-06
WO2000064900A1 (en) 2000-11-02
NO20015065L (no) 2001-10-18
PL354405A1 (en) 2004-01-12
EP1185529B1 (en) 2004-10-13
KR100481757B1 (ko) 2005-04-11
US20020183514A1 (en) 2002-12-05
DK1185529T3 (da) 2005-02-07
CN1279029C (zh) 2006-10-11
MA26782A1 (fr) 2004-12-20
PL200933B1 (pl) 2009-02-27
CO5170444A1 (es) 2002-06-27
PE20010054A1 (es) 2001-02-07
US20040198976A1 (en) 2004-10-07
PT1185529E (pt) 2005-02-28
EP1185529A1 (en) 2002-03-13
ES2228522T3 (es) 2005-04-16
AR023542A1 (es) 2002-09-04
DE60014893D1 (de) 2004-11-18

Similar Documents

Publication Publication Date Title
PL354405A1 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
GB9900416D0 (en) Inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
IL146518A0 (en) Metalloprotease inhibitors
EG23979A (en) Renin inhibitors
AU2001258771A1 (en) -secretase inhibitors
PL362903A1 (en) Renin inhibitors
PL350452A1 (en) Dihetero-substituted metalloprotease inhibitors
PL354979A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
ZA200110053B (en) Factor via inhibitors.
GB0030284D0 (en) Enzyme inhibitors
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
GB9924522D0 (en) Enzyme inhibitors
EP1153022A4 (en) PROTEASE INHIBITORS
PL350941A1 (en) Pyrazole-3-on-derivative as factor xa inhibitors
AU2002400A (en) Telomerase inhibitors
GB2389113B (en) B-secretase inhibitor
GB0229613D0 (en) Biocatalyst inhibitors
GB0109278D0 (en) Enzyme inhibitors
GB9900413D0 (en) Inhibitors
GB9929340D0 (en) Inhibitors
GB9929341D0 (en) Inhibitors
GB9917294D0 (en) Inhibitors
SI1181017T1 (en) Metalloprotease inhibitors